Recursion Pharmaceuticals
RXRX
158 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 43 reducing their positions, and 26 closing their positions.
36% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $765K
35% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 43
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
13% more capital invested
Capital invested by funds: $841M → $953M (+$111M)
0.32% more ownership
Funds ownership: 68.76% → 69.08% (+0.32%)
0% more funds holding
Funds holding: 158 → 158 (0)
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
Top Buyers
Top Sellers
| 1 |
LCM
Laurion Capital Management
New York
|
-$11.5M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$9.51M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.72M |
| 4 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$4.39M |
| 5 |
Millennium Management
New York
|
-$4.31M |
RXRX Hedge Fund Activity: Q2 2023 in Review
158 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2023, worth a combined $953M — up 13% from $841M a quarter earlier.
Fund positioning in RXRX was balanced in Q2 2023: 26 funds opened new positions, 26 closed out, 58 added to existing stakes and 43 trimmed.
The largest buyer was Kinnevik AB, adding an estimated $19.3M. The largest seller was Laurion Capital Management, cutting an estimated $11.5M.
- 158 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $953M of Recursion Pharmaceuticals stock for Q2 2023, up 13% quarter-over-quarter.
- 26 funds opened new Recursion Pharmaceuticals positions in Q2 2023 and 26 closed out, a net change of 0 holders.
- The largest Recursion Pharmaceuticals buyer in Q2 2023 was Kinnevik AB, an estimated $19.3M added.
- The largest Recursion Pharmaceuticals seller in Q2 2023 was Laurion Capital Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2023.